Total synthesis of the antitumor depsipeptide FR-901,228
Total synthesis of the antitumor depsipeptide FR-901,228
复制标题
DOI:
10.1021/ja9613724
复制
发表时间:
1996-07-31
影响因子:
15
通讯作者:
Simon, JA
中科院分区:
文献类型:
--
作者:
Li, KW;Wu, J;Simon, JA
The identification in 1982 of a mutation in the Ha-ras gene provided the first indication of a link between specific molecular changes in regulatory proteins and cancer. 1-3 The mutant ras protein, in which valine replaces glycine-12, was shown capable of inducing morphological changes in mouse fibroblast (NIH-3T3) cells. In these cells the transformed phenotype is indicative of oncogenic activation and correlates with increased tumorigenicity. Recently, a diverse class of natural products and synthetic drugs has been identified that reverses this phenotype and hence “de-transforms” tumorigenic cell lines. Among these are radicicol4, 5 and the tyrphostins, 6 leptomycin B, 7, 8 L-739,749, 9 and trapoxin A. 10, 11 A new member of this class, FR-901,228 (1), was isolated from the culture broth of the terrestrial bacterium Chromobacterium Violaceum using a phenotypic reversion assay of Ha-ras transformed NIH-3T3 cells. FR-901,228 was also shown to be highly active in animal-based assays. 12-14 This finding is not surprising since the ability of a drug to reverse the morphological effect of oncogenic transformation is often accompanied by in vivo antitumor activity. The molecular basis for either activity of FR-901,228 has yet to be identified. 15FR-901,228 (1)(Figure 1) is a bicyclic depsipeptide structurally unrelated to known classes of cyclic peptides. 16 In addition to a dehydro amino acid, Z-butyrine, the depsipeptide incorporates an unusual building block,(3S, 4E)-3-hydroxy-7-mercapto-4-heptenoic acid 5a. A disulfide bond between this thiol and